Evotec, Halozyme

Evotec plunges amid report it's against Halozyme Therapeutics takeover
ADRs quickly plunged 9% in premarket trading amid a report that the company is preparing to fight back against Halozye Therapeutics (HALO) takeover offer. Shares of Halozyme rose 1%. The German drugmaker has hired Morgan Stanley for a takeover defense,
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley. Most Read from BloombergSaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural Divide Over Highway Expansion and Emissions“We feel confident in being able to fund this as a fully cash deal,
Germany’s Evotec Gets Takeover Interest From Halozyme
Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would value the German drug developer at €2 billion ($2.1 billion). Most Read from BloombergUnder Trump,
Halozyme provides update on proposal to combine with Evotec
Halozyme Therapeutics (HALO) provided an update on its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash,
Evotec surges on Halozyme takeover interest
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German biotech for €11.00 per share in cash, or about €2bn.
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc. offered an update on its non-binding takeover proposal at 11 euros a share in cash,
Halozyme plans finance $2.1 takeover of Evotech in cash: report
Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in cash, Bloomberg reported Sunday, quoting Chief Executive Helen Torley. “We feel confident in being able to fund this as a fully cash deal,
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...
Is Evotec SE (EVO) the Best German Stock to Buy Now?
We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where Evotec SE (NASDAQ:EVO) stands against the other German stocks. In Germany, ...
FierceBiotech5d
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an ...
BioPharma Dive5d
Halozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...
FierceBiotech9d
Evotec, after stock-tanking blows, attracts private equity buyout interest: report
Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall ...
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...